Drugs / HBI-2376
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05163028 | Dec 2021 → Dec 2026 expected | malignant colon neoplasm, malignant pancreatic neoplasm, non-small cell lung carcinoma | HUYABIO International, LLC. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-13 | Suzhou Genhouse Bio Co., Ltd. | Results 勤浩医药合作伙伴沪亚生物国际在AACR年会公布SHP2抑制剂HBI-2376（GH21）临床前数据 genhousebio.com ↗
此次公布的临床前研究结果显示，在多种KRAS或EGFR突变的CDX/PDX模型中，GH21均表现出比竞品TNO-155和RMC-4550更强的效力。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-13 | Suzhou Genhouse Bio Co., Ltd. | 勤浩医药合作伙伴沪亚生物国际在AACR年会公布SHP2抑制剂HBI-2376（GH21）临床前数据 genhousebio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBI-2376 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05163028 ↗ |
| Action | Inhibit | “HBI-2376 is a SHP2 Inhibitor” NCT05163028 ↗ |
| Route | Oral | “HBI-2376 as an oral monotherapy” NCT05163028 ↗ |